Article: article from journal or magazin.
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Emerging therapies for gout.
Rheumatic Diseases Clinics of North America
Publication types: Journal Article ; Review Publication Status: ppublish
Over the past decade much has been learned about the mechanisms of crystal-induced inflammation and renal excretion of uric acid, which has led to more specific targeting of gout therapies and a more potent approach to future management of gout. This article outlines agents being developed for more aggressive lowering of urate and more specific anti-inflammatory activity. The emerging urate-lowering therapies include lesinurad, arhalofenate, ulodesine, and levotofisopam. Novel gout-specific anti-inflammatories include the interleukin-1β inhibitors anakinra, canakinumab, and rilonacept, the melanocortins, and caspase inhibitors. The historic shortcomings of current gout treatment may, in part, be overcome by these novel approaches.
Acetamides/therapeutic use, Adrenocorticotropic Hormone/therapeutic use, Antibodies, Monoclonal/therapeutic use, Antirheumatic Agents/therapeutic use, Benzodiazepines/therapeutic use, Gout/drug therapy, Gout Suppressants/therapeutic use, Humans, Imino Furanoses/therapeutic use, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Interleukin-1beta/antagonists & inhibitors, Melanocortins/therapeutic use, Phenylacetates/therapeutic use, Polyethylene Glycols, Pyrimidinones/therapeutic use, Recombinant Fusion Proteins/therapeutic use, Thiazoles, Thioglycolates/therapeutic use, Triazoles/therapeutic use, Urate Oxidase, Uricosuric Agents/therapeutic use
Web of science
Last modification date